- Home
- CDTG vs LSTA Comparison
CDTG vs LSTA Comparison
Compare CDTG & LSTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CDTG
- LSTA
- Stock Information
- Founded
- CDTG 2012
- LSTA 1980
- Country
- CDTG China
- LSTA United States
- Employees
- CDTG N/A
- LSTA N/A
- Industry
- CDTG
- LSTA Misc Health and Biotechnology Services
- Sector
- CDTG
- LSTA Health Care
- Exchange
- CDTG NYSE
- LSTA Nasdaq
- Market Cap
- CDTG 24.5M
- LSTA 20.0M
- IPO Year
- CDTG 2024
- LSTA N/A
- Fundamental
- Price
- CDTG $0.63
- LSTA $2.61
- Analyst Decision
- CDTG
- LSTA Strong Buy
- Analyst Count
- CDTG 0
- LSTA 1
- Target Price
- CDTG N/A
- LSTA $15.00
- AVG Volume (30 Days)
- CDTG 330.9K
- LSTA 15.4K
- Earning Date
- CDTG 05-15-2025
- LSTA 05-08-2025
- Dividend Yield
- CDTG N/A
- LSTA N/A
- EPS Growth
- CDTG N/A
- LSTA N/A
- EPS
- CDTG 0.14
- LSTA N/A
- Revenue
- CDTG $29,765,205.00
- LSTA $1,000,000.00
- Revenue This Year
- CDTG N/A
- LSTA N/A
- Revenue Next Year
- CDTG N/A
- LSTA N/A
- P/E Ratio
- CDTG $4.50
- LSTA N/A
- Revenue Growth
- CDTG N/A
- LSTA N/A
- 52 Week Low
- CDTG $0.52
- LSTA $1.87
- 52 Week High
- CDTG $4.64
- LSTA $4.20
- Technical
- Relative Strength Index (RSI)
- CDTG N/A
- LSTA 56.77
- Support Level
- CDTG N/A
- LSTA $2.43
- Resistance Level
- CDTG N/A
- LSTA $2.78
- Average True Range (ATR)
- CDTG 0.00
- LSTA 0.22
- MACD
- CDTG 0.00
- LSTA 0.02
- Stochastic Oscillator
- CDTG 0.00
- LSTA 67.54
About CDTG CDT ENVIRONMENTAL TECH INV HLDG LTD
CDT Environmental Technology Investment Holdings Ltd is a waste treatment company. The company generates revenue through the design, development, manufacture, sales, installation, operation and maintenance of sewage treatment systems and by providing sewage treatment services. It engages in two business lines namely, rural sewage treatment and septic tank treatment in both urban and rural areas.
About LSTA Lisata Therapeutics Inc.
Lisata Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapies for the treatment of advanced solid tumors and other major diseases. Its product candidate, LSTA1, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively.